← All trials
NCT06036823
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2023
- Primary completion
- Jan 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Sep 14, 2023
- Last posted
- Oct 3, 2023
- Enrollment
- 336
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oman Medical Board Specialty (OMSB)Lead sponsor
- Sultan Qaboos UniversityCollaborator
- Sultan Qaboos UniversityOverall official - principal investigator
- Oman Medical Board Specialty (OMSB)Reponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.